Johnson & Johnson $JNJ Holdings Cut by Perpetual Ltd

Key Points

• Perpetual Ltd reduced its stake in Johnson & Johnson by 6.5%, owning 38,610 shares worth approximately $5.9 million after selling 2,678 shares in the second quarter.
• Johnson & Johnson recently reported $2.77 earnings per share for the last quarter, exceeding analyst expectations of $2.68, and generated $23.74 billion in revenue, up 5.8% year-over-year.
• Several analysts have adjusted their price targets for JNJ, with JPMorgan raising its goal from $185 to $200, reflecting a positive outlook on the stock's performance.

Perpetual Ltd lowered its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 6.5% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 38,610 shares of the company's stock after selling 2,678 shares during the period. Perpetual Ltd's holdings in Johnson & Johnson were worth $5,898,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Highline Wealth Partners LLC grew its position in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson during the 1st quarter valued at about $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson during the 1st quarter valued at about $48,000. von Borstel & Associates Inc. bought a new position in Johnson & Johnson in the 1st quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in Johnson & Johnson in the 1st quarter worth about $52,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

JNJ stock traded down $1.94 on Monday, hitting $174.25. 4,038,321 shares of the company's stock traded hands, compared to its average volume of 8,928,223. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16. The stock has a market cap of $419.65 billion, a price-to-earnings ratio of 18.64, a P/E/G ratio of 2.24 and a beta of 0.40. The stock has a fifty day moving average of $172.80 and a 200-day moving average of $161.64. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same period in the prior year, the business earned $2.82 earnings per share. The business's quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

Analyst Ratings Changes

Several research analysts have commented on JNJ shares. Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Bank of America upped their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Barclays upped their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. The Goldman Sachs Group upped their target price on shares of Johnson & Johnson from $185.00 to $186.00 and gave the stock a "buy" rating in a research report on Friday. Finally, Royal Bank Of Canada increased their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $178.80.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.